EI
RNAC icon

Ellevest Inc’s Cartesian Therapeutics RNAC Stock Holding History

Ellevest Inc’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2
Closed -$77 – 2039
2022
Q4 		$77 Hold
2
– – ﹤0.01% 1770
2022
Q3 		$0 Hold
2
– – ﹤0.01% 1819
2022
Q2 		$0 Buy
+2
New +$59 ﹤0.01% 1641
2021
Q4 		– Sell
-2
Closed – – 1612
2021
Q3 		$0 Buy
+2
New +$242 ﹤0.01% 1544
2021
Q2 		– Sell
-1
Closed – – 1393
2021
Q1 		$0 Hold
1
– – ﹤0.01% 1340
2020
Q4 		$0 Buy
+1
New +$87 ﹤0.01% 1325

Other funds holding RNAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ellevest Inc's RNAC Position: Q1 2023 in Review

Ellevest Inc sold out of Cartesian Therapeutics (RNAC) in Q1 2023, closing a stake of 2 shares — an estimated $77 sold.

Ellevest Inc first reported a position in RNAC in Q4 2020 and held it in 6 quarters. The position peaked at $77 in Q4 2022. 93 funds tracked by Wall St. Rank hold RNAC as of Q1 2023.

  • Ellevest Inc reported no remaining Cartesian Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ellevest Inc sold 2 Cartesian Therapeutics shares in Q1 2023, an estimated $77.
  • Ellevest Inc first reported a position in Cartesian Therapeutics in Q4 2020 and held it in 6 quarters.
  • Ellevest Inc's Cartesian Therapeutics position peaked at $77 in Q4 2022.
  • 93 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2023.

Based on Ellevest Inc's 13F filing for Q1 2023, filed 4 May 2023.